Insider buying last 90 days
No open-market insider purchases were filed for DXCM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DXCM insider filing, plotted on the chart in Gekko.Open DXCM in Gekko
NASDAQ: DXCM
DexCom (DXCM) Stock Analysis & Forecast
$89.35+1.42 (+1.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Gekko Brief
AI summaryDexCom closes at $89.35, up 1.6%, holding above both its 50-day average of $83.84 and its 200-day average of $72.00, with the shorter average above the longer one. The GekkoIndex reads 53.2, placing the stock in the Neutral zone. Against this, price sits 23.5% above the Gekko Fair Value of $72.35, a gap that bears watching given the otherwise constructive trend.
This week's news centers on leadership changes and outside commentary on valuation. DexCom expanded the role of CFO Jereme Sylvain to also serve as Chief Operating Officer, effective 14 September 2026, filling the vacancy left by former COO Jake Leach's move to CEO. The company also appointed Glenn Boehnlein, previously of Stryker Corporation, to its board effective 10 September 2026. Separately, a filing disclosed an insider sale of $679,769, and an outside valuation piece characterized the shares as undervalued relative to a differently calculated intrinsic value.
DexCom's next earnings report is due 29 October 2026 after the close, 39 days out and beyond a typical 20-trading-day holding window. The prior quarter, reported 30 April 2026, produced EPS of $0.56 against a $0.47 estimate and a 6.6% reaction, part of a run of 6 beats in the last 8 quarters, with average absolute reactions of 12.3%. No insider, Congress, or unusual options activity appears in the current windows. Seasonality over the next 20 trading days has averaged -0.9% across 5 years, positive in 2 of them. Analyst coverage stands at 18 buy and 1 hold ratings among 19 firms, with a consensus target of $94.48.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $89.35200-day averageGekko Fair Value $72.35
Key stats
- Market cap
- $33.72B
- P/E ratio
- 34.5
- Forward P/E
- 28.1
- EPS, TTM
- $2.55
- Revenue, TTM
- $4.97B
- Profit margin
- 20.1%
- Dividend yield
- —
- Beta
- 1.42
- Volume
- 14.52M avg 3.97M
- 1-year return
- +16.9%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±7.3%
- 50-day average
- $83.84
- 200-day average
- $72.00
- Next earnings
- Oct 29 after close
- Shares outstanding
- 377.4M
DexCom swing-trade checklist
DexCom scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $89.35 is above the 50-day ($83.84) and 200-day ($72.00) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.2, Neutral
Reading 53.2 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
23.5% above
Price is 23.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.9% on average
From this point in the calendar, the next 20 trading days averaged −0.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
DexCom stock chart and price history
DexCom closed at $89.35 on Sep 18, 2026, +16.9% over the past year, inside a 52-week range of $54.11 to $92.59.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.6%
- 3 months
- +23.3%
- 6 months
- +32.8%
- 1 year
- +16.9%
The full DXCM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DXCM in Gekko
Follow DexCom through every session
Put DXCM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DXCM in GekkoFree for 7 days. No credit card required.
About DexCom
DexCom makes continuous glucose monitoring systems for people living with diabetes, along with tools that let doctors and other clinicians track that data. The company's devices are meant to replace routine finger-prick testing, giving users an ongoing read on glucose levels rather than a single snapshot. Its current lineup includes the G6 system, the newer Dexcom ONE, and a remote monitoring feature called Dexcom Share, with a next-generation G7 device in development.
Beyond its own hardware, DexCom offers a Real-Time API that lets outside developers build its glucose data into other health apps, and it has a licensing arrangement with Verily Life Sciences and Verily Ireland to work on further glucose monitoring products. Sales run directly to clinical specialists, including endocrinologists, physicians, and diabetes educators, who work with patients on managing the condition. The company serves markets both within the United States and abroad.
DexCom was started in 1999 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker DXCM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- dexcom.com
DexCom GekkoIndex: the smart money zone
DexCom’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.2, in the Neutral zone, down 10.6 points over five sessions.
53.2Neutral
Down 10.6 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +2.2% | +4.5% | ||
| Accumulation | 254 | −0.5% | −0.9% | ||
| Neutral (current zone) | 332 | −0.1% | −0.3% | ||
| Distribution | 22 | +0.3% | −0.4% | ||
| Selling | 5 | Too few readings yet | |||
Average DXCM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DXCM price, zone by zone.Track DXCM in Gekko
Is DexCom stock overvalued? Gekko Fair Value
DexCom trades 23.5% above Gekko Fair Value of $72.35, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what DexCom shares are worth, recalculated every trading day.
$72.35
Gekko Fair Value, Sep 19, 2026
23.5% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open DXCM in Gekko
DexCom insider and Congress trading
No open-market insider purchases were filed for DexCom, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DXCM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DXCM, plotted on the chart in Gekko.Open DXCM in Gekko
Buybacks
DexCom has been buying back its own shares.
- Latest authorization
- $1.00B, May 15, 2026
- Bought back, quarter ended Jun 30, 2026
- $603.6M
- As a share of market cap
- 1.79%
- Trailing four quarters
- $1.14B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
1of the funds Gekko tracks holds DXCM.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
DexCom earnings: next date and track record
DexCom reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $0.66
- Revenue estimate
- $1.33B
6 of 8reports beat the EPS estimate
±12.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 30, 2026 AI summary
- What they said
- DexCom reported Q1 2026 revenue growth of 15% (12% organic) versus prior year, driven by strong global CGM demand, new product launches including G7 15-day, and type 2 diabetes market expansion. U.S. momentum was particularly strong in non-insulin type 2 diabetes, with share gains supported by coverage across three largest PBMs covering 6M+ lives. Prime Therapeutics will add coverage by summer, bringing commercial coverage to 7M+ type 2 non-insulin lives by year-end.
- Guidance
- Management expects commercial type 2 non-insulin coverage to exceed 7 million lives by end of 2026. CMS coverage for Medicare type 2 non-insulin population remains a key catalyst viewed as inevitable, representing the largest single growth driver ahead.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 30, 2026 | $0.56 est $0.47 | $1.19B est $1.17B | +6.6% |
| Feb 12, 2026 | $0.68 est $0.65 | $1.26B est $1.25B | +2.7% |
| Oct 30, 2025 | $0.61 est $0.58 | $1.21B est $1.18B | −14.6% |
| Jul 30, 2025 | $0.48 est $0.44 | $1.16B est $1.12B | −9.6% |
| May 1, 2025 | $0.32 est $0.33 | $1.04B est $1.02B | +14.3% |
| Feb 13, 2025 | $0.45 est $0.48 | $1.11B est $1.11B | +6.2% |
| Oct 24, 2024 | $0.45 est $0.44 | $994.2M est $990.4M | +1.3% |
| Jul 25, 2024 | $0.43 est $0.39 | $1.00B est $1.04B | −42.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
DexCom stock forecast and analyst price targets
Analysts’ average 12-month price target for DexCom is $94.48, +5.7% from the last close, from 19 firms rating the stock in the last 90 days.
$94.48consensus 12-month target, +5.7% from the last close
Now $89.35Avg $94.48
Low $82High $105
Each firm’s latest rating in the last 90 days: 19 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Truist Financial | $102 | +14.2% |
| Sep 18 | TD Cowen | $95 | +6.3% |
| Sep 9 | Wells Fargo | $90 | +0.7% |
| Aug 14 | Citi | $105 | +17.5% |
| Aug 13 | Citi | $105 | +17.5% |
−0.3%average 20-day move after past Neutral readings
−0.9%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
DexCom seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, DexCom averaged −0.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.1% | 0 of 5 |
| Next 10 trading days | −3.3% | 0 of 5 |
| Next 15 trading days | −0.8% | 2 of 5 |
| Next 20 trading days | −0.9% | 2 of 5 |
| Next 30 trading days | +6.8% | 3 of 5 |
For scale, DXCM’s typical 20-trading-day move in either direction is about 7.3%.
DexCom market cap and key statistics
DexCom’s market cap is $33.72B, with a P/E ratio of 34.5 and revenue of $4.97B over the last twelve months.
Valuation
- Market cap
- $33.72B
- P/E ratio
- 34.5
- Forward P/E
- 28.1
- EPS, TTM
- $2.55
- Gekko Fair Value
- $72.35
Trading
- Volume
- 14.52M
- Avg volume, 20 days
- 3.97M
- 52-week high
- $92.59
- 52-week low
- $54.11
- Shares outstanding
- 377.4M
Financials
- Revenue, TTM
- $4.97B
- Profit margin
- 20.1%
- Return on equity
- 38.5%
- Quarterly earnings growth, YoY
- +43.6%
Risk and income
- Beta
- 1.42
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±7.3%
DexCom stock news this week
Coverage of DexCom this week reads positive: 5 positive, 0 neutral and 1 negative headlines.
- Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filingwww.marketscreener.com, Sep 16
- Dexcom gives CFO Jereme Sylvain expanded roleMedTech Dive, Sep 16
- DXCM Looks 17.4% Undervalued on GF Value™GuruFocus, Sep 14
- Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026www.marketscreener.com, Sep 14
- Here's Why You Should Retain DexCom Stock in Your Portfolio for NowYahoo Finance Singapore, Sep 14
- Dexcom Promotes Jereme Sylvain to Chief Operating OfficerBusiness Wire, Sep 14
DexCom peers
DexCom’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
DexCom stock FAQ
What is DexCom’s market cap?
DexCom’s market cap is $33.72B at the Sep 18, 2026 close of $89.35, with 377.4M shares outstanding. The shares trade on a P/E ratio of 34.5.
What is the DexCom stock forecast?
The consensus analyst 12-month price target for DexCom is $94.48, +5.7% from the last close. Of the 19 firms that rated the stock in the last 90 days, 18 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is DexCom stock overvalued or undervalued?
On Gekko’s estimate DexCom is overvalued: the Sep 18, 2026 close of $89.35 is 23.5% above Gekko Fair Value of $72.35. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does DexCom report earnings next?
DexCom is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $0.66 per share on revenue of $1.33B. DexCom beat the earnings estimate in 6 of its last 8 reports, moving 12.3% on average across the report.
What is DexCom’s 52-week high and low?
DexCom’s 52-week high is $92.59 and its 52-week low is $54.11; it closed at $89.35 on Sep 18, 2026, +16.9% over the past year.
Is DexCom stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See DexCom the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.